Problem=Opportunity

✓ Reduced efficacy of actual vaccines
✓ Short duration of immunity
✓ No cross-protection against different strains
✓ Biosafety issues
✓ Imperfect costs for end users

Vaccination offers an effective, inexpensive way to safeguarding the health and welfare of animals, however there is still room for innovations
VP2 protein is a structural protein of the Infectious Bursitis virus (IBDV) that naturally autoassemble forming Virus-Like Particles (VLPs).
Ch-VLP Platform: Technology Basis

Displaying selected epitopes, we can design chimeric virus-like particles to stimulate the most adequate response against the target pathology.
Ch-VLP Platform: Technology Basis
Ch-VLP Platform: Main Advantages

- **High Efficiency**: Boosted and durable host immune response.
• **High Efficiency**: Boosted and durable host immune response.
• **Differentiating Infected from Vaccinated Animals** (DIVA).
• **High Efficiency**: Boosted and durable host immune response.
• **Differentiating Infected from Vaccinated Animals** (DIVA).
• **Biosafety**: without genetic material it is not able to autoreplicate.
• **High Efficiency:** Boosted and durable host immune response.

• **Differentiating Infected from Vaccinated Animals** (DIVA).

• **Biosafety:** without genetic material it is not able to autoreplicate.

• **High flexibility:** Formulation of different Ch-VLPs monocomponents or displaying different antigens (cellular, humoral or both), consensus sequences, multiple targets...
**Ch-VLP Platform: Main Advantages**

- **High Efficiency:** Boosted and durable host immune response.
- **Differentiating Infected from Vaccinated Animals (DIVA).**
- **Biosafety:** without genetic material it is not able to autoreplicate.
- **High flexibility:** Formulation of different Ch-VLPs monocomponents or displaying different antigens (cellular, humoral or both), consensus sequences, multiple targets...
- **Low-cost production system:** Already validated in several hosts
Our Ch-VLPs are ideal vehicles to generate vaccines against animal pathologies in which protection is dependent on one or few well-known epitopes.
Our products portfolio already contents products against the main impacting diseases in the veterinary field, targeting a global market of >1 Billion of Euros.

- Well recognized and challenging diseases
- Globally distributed diseases
- Competitive landscape
VLPbio is a technological company that provide a **first-class technology** for the development of new vaccines with **differentiating properties** to be successfully applied in animal health.

The company has a **strong and diversified portfolio of products on development** for the most important diseases not properly covered.

**Thank you**